- Report
- March 2025
- 181 Pages
Global
From €3222EUR$3,545USD£2,736GBP
€3580EUR$3,939USD£3,040GBP
- Report
- January 2025
- 165 Pages
Global
From €2590EUR$2,850USD£2,200GBP
- Report
- November 2024
- 180 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- December 2024
- 150 Pages
Global
From €3409EUR$3,750USD£2,894GBP
- Report
- January 2022
- 60 Pages
Global
From €3590EUR$3,950USD£3,049GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4499EUR$4,950USD£3,821GBP
- Report
- November 2023
- 190 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- September 2023
- 116 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- September 2022
- 104 Pages
Middle East, Africa
From €1363EUR$1,500USD£1,158GBP
- Report
- September 2022
- 104 Pages
Asia Pacific
From €1363EUR$1,500USD£1,158GBP
- Report
- September 2022
- 104 Pages
Europe
From €1363EUR$1,500USD£1,158GBP
- Report
- August 2024
- 91 Pages
Global
From €3500EUR$4,125USD£3,076GBP
- Book
- October 2019
- 382 Pages
- Book
- May 2023
- 272 Pages
- Book
- December 2022
- 400 Pages
- Book
- April 2018
- 528 Pages

Congestive Heart Failure (CHF) is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is a common form of heart disease and is the leading cause of hospitalization in the United States. CHF is a progressive condition, meaning that it can worsen over time. Symptoms of CHF include shortness of breath, fatigue, and swelling in the legs and feet. Treatment for CHF typically includes lifestyle changes, medications, and in some cases, surgery.
The CHF market within the context of cardiology is a rapidly growing one. It is estimated that over 5 million people in the United States are living with CHF, and this number is expected to increase in the coming years. As such, there is a need for new and innovative treatments to help manage the condition.
Some companies in the CHF market include Novartis, Amgen, and Merck. These companies are developing new treatments and therapies to help manage the condition. Additionally, there are a number of smaller companies that are developing new technologies to help diagnose and monitor CHF. Show Less Read more